Eleven years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians, researchers, medical experts and professionals for the 11th time. LabRoots aims to elevate the level of collaboration and in turn, advance clinical diagnostics, research and medicine.
On November 12, 2020 thousands will join in a discussion of the continuous progress made with advances in laboratory testing and patient care and treatment. With new technologies and treatments available, updates in regulatory processes are also necessary to ensure patient safety and proper practices.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Clinical Diagnostics Virtual Event. Submission is free; submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRclinical to follow the conversation!
POSTER SUBMISSION GUIDELINES
Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.
SUBMIT YOUR ABSTRACT
Enter the following information to this Submission Form:
All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.
If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.
Questions? Email Posters@LabRoots.com
Dr. Jared R. Auclair is currently the Associate Dean of Professional Programs in the College of Science at Northeastern University and Associate Teaching Professor in the Department of chemistry and chemical biology. In addition, Dr. Auclair is the Director of the Biopharmaceutical Analysis Laboratory (BATL), the Asia-Pacific Economic Cooperation Center of Regulatory Excellence in Biotherapeutics and Advanced Therapies, and oversees the International Council for Harmonisation training. Lastly, Prof. Auclair serves as the Technical Supervisor for the Life Science Testing Center at Northeastern University, which is a state and CLIA-certified lab. Dr. Auclair collaborates with both academic researchers, industry, and government in the area of biopharmaceutical development and analysis. He has expertise in molecular biology, protein biochemistry, analytical chemistry, protein crystallography, and biological mass spectrometry; and is interested in use-inspired research for the biotechnology industry.
As a senior Bioinformatician Ajay is responsible for custom services related to API integration from external systems to Qiagen Clinical Insight . He is also responsible for custom reporting services from the QCI platform including automated variant reporting policies and data export in various different formats. Ajay has a Masters in Bioinformatics from Northeastern University.
Jessica Boyd is a Clinical Biochemist at Alberta Precision Laboratories (Calgary) and a Clinical Associate Professor in the Cumming School of Medicine at the University of Calgary. Dr. Boyd completed her Ph.D. in Analytical and Environmental Toxicology at the University of Alberta in 2012 and Clinical Biochemistry Fellowship training at Calgary Laboratory Services/University of Calgary in 2015. She is currently the co-director of the Analytical Toxicology Laboratory at APL-Calgary. Her areas of interest include urine drugs of abuse testing, therapeutic drug monitoring and endocrine markers.
Jeannie L. Callum, MD, FRCPC, is a Transfusion Medicine Specialist and Hematologist at Sunnybrook Health Sciences Center in Toronto and Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She is the Director of Utilization for the Department of Laboratory Medicine and Molecular Diagnostics. She also serves as the sponsor lead for the Ontario Regional Blood Coordinating Network for Central Ontario. Her primary interests in transfusion medicine include error tracking and the management of the coagulopathy associated with traumatic injury and post cardiac surgery. She has been involved with numerous transfusion clinical trials including ABLE, PROPPR, FIIRST, TACS and FIBRES. She has written extensively about issues in transfusion medicine, publishing more than 100 peer-reviewed articles and authoring numerous book chapters. She also was the lead author on the Provincial (Ontario) transfusion handbook titled “Bloody Easy,” now preparing its fourth edition. In addition, she is on the editorial board for the “Transfusion Medicine Reviews” and “Transfusion” journals.
Dr. Lawrence de Koning is an Associate Professor at the University of Calgary and Clinical Biochemist with Alberta Precision Laboratories. He directs the pediatric clinical biochemistry testing laboratory at Alberta Children’s Hospital in Calgary, Alberta, Canada. Dr. de Koning’s clinical interests are in pediatric clinical biochemistry as it relates to the acute and chronic care of children with cardiac, metabolic and endocrine disorders. His research interests are in laboratory quality improvement and in the epidemiology of childhood and adult conditions with significant morbidity and mortality.
Prof. (Dr) Pradeep Kumar Dabla is an experienced Chairperson with a demonstrated history of more than 17 yrs of Leadership & Administration while working in the hospital & health care industry. He is a laboratory physician skilled in Medical Devices, Molecular Biology, Biotechnology, Laboratory Medicine and Clinical Research. He is a strong research professional with a NABL Assessor ISO 15189:2012 focused in Medical Laboratory from National Accreditation Board for Testing and Calibration Laboratories (NABL), Quality Council, Govt. of India. He has assessed more than 100 medical labs for NABL accreditation till date. He has been closely associated with National Accreditation Board for Hospitals & Healthcare Providers (NABH) for preparing & maintaining quality services for Chacha Nehru Bal Chikitsalya (CNBC), first public sector superspeciality hospital to receive accreditation while working as Head, Deptt of Biochemistry & all labs. Currently, he is working as a Professor, Department of Biochemistry, G.B.Pant Institute of Postgraduate Medical Education & Research (GIPMER), Associated Maulana Azad Medical College (MAMC), Govt of NCT of Delhi. He is also serving as Consultant, International Core Committee of IFCC Task Force for Young Scientists (IFCC-TFYS), Core Member APFCB-Communication & Publication Committee and Member IFCC C-MHBLM (Emerging Technologies Division). He demonstrated leadership skills with team ability and served IFCC as Chair IFCC-TFYS (2015-2019) while working for networking, training, education and support programmes for young colleagues. He has completed MBBS from Maulana Azad Medical College, Delhi University and MD (Biochemistry) from Lady Hardinge Medical College, Delhi University, India. Further, to increase the proficiency in management, he pursued Post-graduation in the Business Administration & Hospital Management. He is also qualified with Advanced Training in Supply Chain Management, Govt. of NCT Delhi, India. Due to keen interest in research and laboratory medicine, he has been awarded Thrice for his research work in “Postmenopausal Women CAD Risk & Gene Polymorphism” and “Diabetic CAD Risk” and received other Five Awards & Travel Grants at International level and been invited many times as speaker, chair at National & International congresses. He has more than 40 research papers to his credit in reputed National & International journals apart from 4 book chapters, 2 books and more than 30 abstracts as a part of invited talks and papers presented. He is associated with reputed journals as editor, reviewer and advisory board member.
Paul R. Johnson, Ph.D., MT(ASCP), D(ABCC), FAACC is an Associate Professor at Upstate Medical University in Syracuse, New York, where he teaches laboratory medicine courses in clinical biochemistry and statistics. He earned a Ph.D. degree in Biochemistry & Molecular Biology from the University of Louisville (KY) School of Medicine, and completed a medical technology fellowship in the Department of Pathology at Newton-Wellesley Hospital (MA). Dr. Johnson’s professional career in clinical pathology spans over 20 years. He has held positions in clinical chemistry, hematology, and immunology laboratories as a medical laboratory scientist; technical specialist at the College of American Pathologists (CAP); and was technical manager of a specialized diagnostic laboratory with focus on cardiovascular disease biomarker testing. At Upstate Medical University, his clinical research has focused on diagnostic utility of concussion injury biomarkers in human subjects, with secondary focus on applied statistics related to human biological variation. His work led to invited presentations at several clinical science conferences, along with recent publications on these topics in high-impact scientific journals including Clinical Chemistry and PLoS One. He serves as peer-reviewer for several leading journals in the laboratory medicine field. Dr. Johnson holds professional board certifications from the American Society for Clinical Pathology and the American Board of Clinical Chemistry. In 2019, he was inducted as a Fellow into the Academy of the American Association for Clinical Chemistry.
Dzenita is a Clinical Development Engineer at Visiopharm. She holds a M.Sc. in Biomedical Engineering with a focus on medical image analysis from the Technical University of Denmark. Over the last 5 years, she has been involved in the development of CE-IVD APPs for the Visiopharm software platform, including data sourcing and management, and she specializes in external collaborations and projects with a clinical/CE-IVD/FDA scope.
Dr. Frank Ong is the Chief Medical and Scientific Officer at Everlywell, the digital health company poised to disrupt the 25 billion dollar lab testing industry by providing consumers with at-home lab testing kits that include insightful, easy-to-understand results. Dr. Ong leads the company's medical affairs including clinical laboratory operations, research, and clinical development including new test development. Prior to joining Everlywell, Dr. Ong held leadership positions at Guardant Health, Roche Diagnostics, and Illumina and served as a faculty member and researcher at Cedars-Sinai Medical Center, where he received research grants from the National Institutes of Health (NIH). He earned his medical degree from the Keck School of Medicine at the University of Southern California and holds graduate certificates in clinical and translational investigation, biodesign and medical device innovation and clinical trial administration from Stanford University, UCLA and University of California San Diego. He served his residency in the Department of Family Medicine at UCLA's Geffen School of Medicine. He resides in Austin, Texas
I have the expertise, leadership, training, and motivation necessary to successfully carry out the proposed research project. I have a broad background in biology, with specific training and expertise in public health microbiology, particularly pertaining to serological responses to infectious diseases, including emerging infectious diseases. My work includes clinical laboratory diagnostics research across a broad range of disciplines. My particular focus currently is development and evaluation of high-quality clinical laboratory diagnostic tests, particularly for emerging or under-studied pathogens. Presently, work in our laboratory is focused on evaluation and development of serological assays for detection of antibodies against SARS-CoV-2.
My early publications addressed the role of mobile genetic elements in human cancers. My work has led to several novel findings in the field, including the clonal variation of human mobile elements in different cancers, the contribution of mobile elements to DNA double strand break repair, description of the extensive variation in full-length/active mobile elements between individuals, and the role of several DNA repair pathways, including nucleotide excision repair and transcription-coupled repair, in limiting damage from mobile elements in vivo. Additionally, my work developed several novel tools that are now widely used in the field of mobile elements including a high-throughput sequencing approach for mobile element identification, and a droplet digital PCR approach for detection of rare mobile element insertions in tumors.
Additionally, I have made substantial contributions to the field of infectious diseases through work on the human parasite Plasmodium falciparum where my work focused on identifying potential druggable targets in the malaria parasite. Together with collaborators, I have described a receptor activated kinase required for intraerythrocytic proliferation, identified a novel parasite cyclin H homolog required for cytokinesis of blood-stage parasites, identified a essential contractile ring protein that controls cell division in P. falciparum, and developed a novel anti-parasitic compound that retains activity against artemisinin-resistant parasite strains.
My recent clinical laboratory work includes evaluation of molecular and serological assays for the detection of Zika virus and Zika virus antibodies, and more recently evaluation and development of molecular and serological assays for the detection of SARS-CoV-2 and SARS-CoV-2 antibodies. Our early work has shown a significant link between the severity of patient symptoms and the subsequent immune response.
During her career, Ms. Swanson has worked with a wide range of professionals in health care and business to develop and facilitate new programs. Ms. Swanson has been recognized as a leader and mentor, served on several Board of Director positions and as an elected officer for state and national groups. Ms. Swanson practiced pharmacy in a variety of environments including inpatient, outpatient, clinical, managed care, and research. In addition to her practice experience, she has overseen local and national programs for quality management, performance improvement and measurement systems. More recently, Ms. Swanson worked as the Director of Clinical Solutions at TriCore Reference Laboratories where she led the development and implementation of state-wide population health initiatives for high prevalence conditions in New Mexico using laboratory data. Currently she is a member of the Project Santa Fe Foundation Faculty working with multi-site groups to demonstrate the value of laboratory insights to improve patient care and reduce total costs.
Professor Xiaowu (Shirley) Tang joined the Department of Chemistry & Waterloo Institute for Nanotechnology (WIN) at the University of Waterloo (UW) in 2006. Currently, she is the Associate Dean of Science, Research, and a member of the Board of Directors for WIN. During 2014-2017, she served as the Director of Nanotechnology Engineering (NE) program, Canada’s only undergraduate NE program. Prior to joining UW, she received her Ph.D. from Massachusetts Institute of Technology (MIT) and pursued postdoctoral work at Stanford University. She also had 3 years of industrial experience in Silicon Valley, California, and is a co-founder of LeNano Diagnostics, Inc, a company incorporated in 2016. The Tang group is internationally recognized for its pioneer work on hybrid nanobio- materials and devices, with contributions particularly to the material, surface, and physical chemistries dealing with carbon nanostructures. Of significance is the development of biomarker sensing platforms for early diagnosis and management of chronic diseases. A low-cost point-of-care testing platform based on carbon nanotube biosensors is currently under transition to commercialization. Another noteworthy aspect of Tang’s research is the creation of a class of hybrid scaffold materials for tissue engineering, which integrates functional nanostructures and biopolymers to offer extraordinary mechanical, electrical, and rheological properties. The new materials, combined with 3D-printing and microfabrication, could provide disruptive technologies for the fabrication of tissues/organs, which can find important applications in drug screening and regenerative medicine. Her work has led to publications on prestigious journals, such as Nature Nanotechnology, Nature Biotechnology, Journal of American Chemical Society, Advanced Materials, and Nano Letters, as well as patent applications, multiple industrial partnerships, media reports, and invited lectures. Prof. Tang received the Leader’s Opportunity Award from Canada Foundation for Innovation (CFI) in 2008 and the Stars in Global Health Award from Grand Challenges Canada in 2012, Award for Outstanding Mid-Career Achievements in Nanoscience and Nanotechnology, NanoOntario, in 2018.
Sean Taylor holds a Ph.D. and an MBA from McGill University and has spent the past ten years publishing articles, providing seminars, workshops and training videos to help the global scientific community achieve excellent data from western blotting, qPCR and digital PCR experiments. He has managed teams of Field Application Scientists (FAS) in Canada for over a decade who have helped thousands of scientists achieve their research goals. In his current role as North American FAS Manager for GenScript, he leads a dedicated team to continue the tradition of providing pertinent and timely information to help the scientific community overcome research hurdles to accelerate the production of high quality, publishable data, cost-effectively.
Alexander Wolf is a Senior Scientist in Sample Preparation Technologies, Molecular Diagnostics Development at QIAGEN GmbH. Following completion of a PhD in Biochemistry and a 3-year post-doctoral fellowship at the Institute of Pharmacology Giessen, Germany, Dr. Wolf joined QIAGEN in 2012 and has focused on the liquid biopsy portfolio for the past 8 years. As technical lead of the Molecular Diagnostics Development team, he was mainly responsible for the development of the QS DSP Circulating DNA Kit which launched in 2017 and remains dedicated to customer support of this product today.
DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics.
The American Biological Safety Association (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. The Association's goals are to provide a professional association that represents the ...See more See less
PENTAPHARM has a long-standing tradition as an innovative and reliable supplier of active ingredients for the pharmaceutical, diagnostic and cosmetic industry. Our roots as researchers, developers and manufacturers of state-of-the-art products reach back to 1948. PENTAPHARM ...See more See less
Luminex's mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and ...See more See less
Manuscriptedit specializes in providing services in Scientific & English editing, proofreading, medical writing, academic writing, formatting and publication support. Within a short span of time, the company has grown rapidly to be counted among the world's leading service ...See more See less
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and ...See more See less
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a ...See more See less
Visiopharm® is a world leader in Augmented Pathology™ solutions; that comprise precision pathology and high-throughput pathology for tissue-diagnostics and research. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and ...See more See less
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological ...See more See less
Thermo Fisher Scientific is the world leader in serving science, our mission is to enable our customers to make the world healthier, cleaner and safer. High-content screening/analysis (HCS) was invented by and registered as a trademark of Cellomics, which is now part of Thermo ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels, Belgium. He is the head of the department of Clinical Biochemistry of the Cliniques Universitaires Saint Luc. He is also ...See more See less
Brian McNally received his doctorate in Cell & Molecular Biology at University of Texas Southwestern Medical Center, where he focused on the transcriptional mechanisms governing polycystic kidney disease, renal cancer and development. His post-doctoral fellowship concentrated on ...See more See less
Dr. Paul Yip is Division Head of Clinical Biochemistry at Sunnybrook Health Sciences Center in Toronto, and is Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. Prior to his current position, he was at University Health ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events